Routine

Paget disease of bone (osteitis deformans)

calcium-bone · Metabolic
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Focal disordered bone remodelling with accelerated turnover producing enlarged, structurally weak, deformed bone. Often asymptomatic (incidental raised ALP or X-ray). Common sites: pelvis, femur, skull, spine, tibia. Usually older adults; may cause bone pain, deformity, fracture, nerve compression (deafness), rarely high-output cardiac failure or osteosarcoma.

Red flags

  • Sudden increase in bone pain, soft-tissue mass or rapid growth — exclude osteosarcoma (rare but serious)
  • New neurological deficit, cord compression, or hearing loss from skull/spine involvement
  • Pathological fracture through pagetic bone
  • High-output cardiac failure in extensive polyostotic disease

Assessment

Differential diagnosis

  • Metastatic bone disease / myeloma (sclerotic/lytic lesions)
  • Primary bone tumour (osteosarcoma — rare Paget complication)
  • Osteomalacia / renal osteodystrophy (raised ALP)
  • Hyperparathyroid bone disease
  • Fibrous dysplasia

Investigations

  • Serum ALP (raised — marker of activity and treatment response) with normal calcium/phosphate
  • Isolated raised bone ALP with normal LFTs is the classic incidental clue; bone-specific ALP or P1NP if liver disease present
  • X-ray of affected area (cortical thickening, coarse trabeculae, bone expansion, lytic/sclerotic mix)
  • Radionuclide bone scan to map extent of disease
  • Calcium (usually normal; rises if immobilised), vitamin D (replete before bisphosphonate), U&E/eGFR
  • Audiometry if skull involvement; MRI/CT if nerve compression or malignant change suspected

Management

  • Confirm diagnosis (X-ray +/- bone scan) and assess activity (ALP) and complications
  • Ensure vitamin D and calcium replete BEFORE giving IV bisphosphonate (prevents hypocalcaemia)
  • Treat if symptomatic (bone pain), or to protect at-risk sites (weight-bearing bone, skull base, pre-surgery, nerve compression)
  • Single IV zoledronic acid infusion is treatment of choice — produces prolonged remission
  • Analgesia for pain; physiotherapy and orthotics for deformity
  • Monitor ALP to judge response and relapse; re-treat if ALP rises and symptoms recur (usually >1 year later)
  • Refer for surgery (joint replacement, fracture fixation, nerve decompression) as needed; sudden pain increase → exclude sarcoma

Drugs & doses

Zoledronic acid 5 mg IV single infusion over ≥15 min (treatment of choice; ensure eGFR ≥35 and vitamin D replete)
Calcium 500 mg elemental twice daily + vitamin D for ~10-14 days after zoledronate to prevent hypocalcaemia
Risedronate 30 mg PO od for 2 months — oral alternative if IV contraindicated [verify local]
Paracetamol / NSAID for bone pain
Re-treat with zoledronic acid only on biochemical/symptomatic relapse (usually ≥1 year later)

Disposition

Outpatient endocrine/metabolic bone or rheumatology clinic. Admit only for fracture, cord/nerve compression or suspected malignant change.

Complications & pitfalls

  • Deformity (bowing), pathological fracture, secondary osteoarthritis
  • Nerve compression (deafness, radiculopathy, basilar invagination)
  • Osteosarcoma (<1%) — poor prognosis
  • High-output heart failure (extensive disease); hypercalcaemia if immobilised

Exam pearls

  • Think Paget in an older patient with an isolated raised ALP and normal calcium/phosphate/LFTs.
  • Endocrine Society guidance: a single 5 mg IV zoledronic acid infusion is the treatment of choice and gives durable remission; monitor ALP for response/relapse.
  • Always replete vitamin D/calcium before IV bisphosphonate to avoid symptomatic hypocalcaemia.
  • ALP (or bone turnover markers) tracks disease activity and response to therapy.
  • A fresh focus of pain in long-standing Paget demands imaging to exclude sarcomatous change.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.